Minimally invasive surgical methods for the treatment of benign prostatic hyperplasia, as an alternative to classic desobstructive procedures
Authors:
Lukáš Fišer 1; Milan Čermák 1; Lubomír Hyršl 1; Jiří Kočárek 1,2
Authors‘ workplace:
Urologické oddělení, Oblastní nemocnice Kladno, a. s., Kladno
1; Urologická klinika, 1. lékařská fakulta, Univerzita Karlova v Praze
2
Published in:
Ces Urol 2020; 24(3): 191-206
Category:
Review article
Overview
Fišer L, Čermák M, Hyršl L, Kočárek J. Minimally invasive surgical methods for the treatment of benign prostatic hyperplasia as an alternative to classic desobstructive procedures.
Since 1885 and 1886, when Belfield and Dittel performed the first transvesical prostatectomy (TVPE) described in the literature, and since 1926, when Maximilian Stern performed the first transurethral resection of the prostate (TURP), these techniques are considered the “gold standard” in surgical treatment of benign prostatic enlargement (BPH). Both surgical methods lead to a significant improvement in subjective, functional and laboratory results, namely a reduction in the International Prostate Symptom Score Questionnaire (IPSS), an increase in maximum urine flow rate (Qmax), a reduction in post-micturition residue volume (PMR), a reduction in prostate volume (PV) and in some cases to reduce the value of prostate specific antigen (PSA). Nevertheless, we would find here several “defects in beauty”. The main disadvantages of the above surgical procedures include the need for hospitalization, anesthesia and bladder catheterization, plus high perioperative morbidity and possible postoperative complications such as bleeding, infections, urinary retention, urinary incontinence, urethral strictures and sexual dysfunction. Therefore, many new surgical techniques have been developed over the years to minimize these shortcomings. Some of them have entered the standard algorithm for surgical treatment of BPH, such as transurethral prostate enucleation (TUEP), prostate enucleation by holmium laser (HoLEP) or thulium laser (ThuLEP), or photoselective prostate vaporization (PVP). Others have not been fully established, such as transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA) and prostate stents.
Despite the excellent surgical results of the above-mentioned desobstructive procedures in the treatment of BPH, there remain a number of men who cannot or do not want to un‑ dergo them. The most common reasons for the impossibility of performing surgical treatment include the patient’s polymorbidity, fear of possible perioperative and postoperative complications. That is why there is intensive development of new minimally invasive surgical techniques that would not require hospitalization, anesthesia and catheterization and at the same time would lead to a reduction or elimination of side effects of standard surgical treatment of BPH. These methods include the AquaBeam® system, the UroLift® system, the Rezūm® system and the TIND system.
Keywords:
AquaBeam® – benign prostate hyperplasia (BPH) – minimally invasive surgical methods – Rezūm® – TIND – UroLift®
Sources
1. Srinivasan A, Wang R. An Update on Minimally Invasive Surgery for Benign Prostatic Hyperplasia: Techniques, Risks, and Efficacy. The world journal of men’s health, 2019.
2. Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation‑image‑guided robot‑assisted waterjet ablation of the prostate: initial clinical experience. BJU international. 2016; 117(6): 923–929.
3. Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. The Journal of urology. 2017; 197(6): 1565–1572.
4. Gilling P, Barber N, Bidair M, et al. WATER: a double‑blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. The Journal of urology. 2018; 199(5): 1252–1261.
5. Gilling P, Barber N, Bidair M, et al. Two‑Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained. Advances in therapy. 2019; 36(6): 1326–1336.
6. Pham H, Sharma P. Emerging, newly‑approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. The Canadian journal of urology. 2018; 25(2): 9229.
7. Woo HH, Chin PT, McNicholas, TA, et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU international. 2011; 108(1): 82–88.
8. Chin PT, Bolton DM, Jack G, et al. Prostatic urethral lift: two‑year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2012; 79(1): 5–11.
9. Roehrborn CG, Rukstalis DB, Barkin J, et al. Three year results of the prostatic urethral LIFT study. The Canadian journal of urology. 2015; 22(3): 7772–7782.
10. Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral LIFT study. The Canadian journal of urology. 2017; 24(3): 8802–8813.
11. Gratzke C, Barber N, Speakman MJ, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH 6 prospective, multicentre, randomized study. BJU international. 2017; 119(5): 767–775.
12. Sønksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. European urology. 2015; 68(4): 643–652.
13. Rukstalis D, Barber NJ, Speakman MJ, et al. Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate cancer and prostatic diseases. 2018: 1.
14. Das A, Leong J, Roehrborn C. Office‑based therapies for benign prostatic hyperplasia: a review and update. The Canadian journal of urology. 2019; 26(4S1): 2–7.
15. Cantrill CH, Zorn KC, Elterman DS, Gonzalez RR. The Rezūm System – a minimally invasive water vapor thermal therapy for obstructive benign prostatic hyperplasia. The Canadian journal of urology. 2019; 26: 3.
16. Westwood J, Geraghty R, Jones P, Rai BP, Somani BK. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Therapeutic advances in urology. 2018; 10(11): 327–333.
17. Dixon CM, Cedano ER, Pacik D, et al. Two‑year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Research and reports in urology. 2016; 8: 207.
18. McVary KT, Roehrborn CG. Three‑year outcomes of the prospective, randomized controlled Rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2018; 111: 1–9.
19. Darson MF, Alexander EE, Schiffman ZJ, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Research and reports in urology. 2017; 9: 159.
20. Porpiglia F, Fiori C, Bertolo R, et al. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow‑up. BJU international. 2015; 116(2): 278–287.
21. Porpiglia F, Fiori C, Bertolo R, et al. 3-Year follow‑up of temporary implantable nitinol device implan‑ tation for the treatment of benign prostatic obstruction. BJU international. 2018; 122(1): 106–112.
22. Porpiglia, F, Fiori, C, Amparore, D, et al. Second generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow up. BJU international. 2019; 123(6): 1061–1069.
Labels
Paediatric urologist Nephrology UrologyArticle was published in
Czech Urology
2020 Issue 3
Most read in this issue
- Minimally invasive surgical methods for the treatment of benign prostatic hyperplasia, as an alternative to classic desobstructive procedures
- Prevention of recurrent cystitis with intravesical instillation of hyaluronic acid Flaveran®
- Prostate carcinoma metastasis to the testis
- Bladder neck preservation with RARP